INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3301, 29789, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3302, 29790, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3303, 3338, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3304, 4646, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3305, 4648, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3306, 7294, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3307, 7296, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3308, 7297, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3309, 7299, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3310, 7308, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3311, 7311, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3312, 7312, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3313, 7317, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3314, 11847, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3315, 12731, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3316, 17249, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3317, 21222, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3318, 21800, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3319, 21801, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3320, 21803, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3321, 21804, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3322, 21805, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3323, 21806, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3324, 21808, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3325, 21809, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3326, 21811, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3327, 21812, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3328, 21815, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3329, 21816, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3330, 21821, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3331, 21822, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3332, 21824, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3333, 21827, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3334, 21829, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3335, 22271, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3336, 25301, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3337, 28382, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3338, 28676, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3339, 29789, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3340, 29790, 'Lidocaine', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3341, 3338, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3342, 4646, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3343, 4648, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3344, 7294, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3345, 7296, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3346, 7297, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3347, 7299, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3348, 7308, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3349, 7311, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3350, 7312, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3351, 7317, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3352, 11847, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3353, 12731, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3354, 17249, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3355, 21222, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3356, 21800, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3357, 21801, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3358, 21803, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3359, 21804, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3360, 21805, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3361, 21806, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3362, 21808, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3363, 21809, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3364, 21811, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3365, 21812, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3366, 21815, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3367, 21816, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3368, 21821, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3369, 21822, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3370, 21824, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3371, 21827, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3372, 21829, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3373, 22271, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3374, 25301, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3375, 28382, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3376, 28676, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3377, 29789, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3378, 29790, 'Lidocaine', 'Liver Diseases', 'Lidocaine is rapidly and extensively metabolized by the liver.  Less than 10% is eliminated unchanged in the urine.  Several inactive and two active forms (MEGX and GX) have been identified.  MEGX and GX exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow.  Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary.  Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3379, 3338, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3380, 4646, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3381, 4648, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3382, 7294, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3383, 7296, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3384, 7297, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3385, 7299, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3386, 7308, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3387, 7311, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3388, 7312, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3389, 7317, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3390, 11847, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3391, 12731, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3392, 17249, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3393, 21222, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3394, 21800, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3395, 21801, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3396, 21803, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3397, 21804, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3398, 21805, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3399, 21806, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3400, 21808, 'Lidocaine', 'Kidney Diseases', 'Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.  GX accumulates during prolonged intravenous lidocaine infusion.  Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function.  Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.', '3', '', 'DDInter', 0);
